Placebo and nocebo effects in gambling disorder pharmacological trials: a meta-analysis
Authors:
- Konstantinos IoannidisKIKonstantinos Ioannidis
- Nathan T.M. HunekeNHNathan T.M. Huneke
- Jeremy E. SollyJSJeremy E. Solly
- Guilherme Fusetto VeronesiGVGuilherme Fusetto Veronesi
- Charidimos TzagarakisCTCharidimos Tzagarakis
- Valeria ParlatiniVPValeria Parlatini
- Samuel J. WestwoodSWSamuel J. Westwood
- Cinzia Del GiovaneCGCinzia Del Giovane
- David S. BaldwinDBDavid S. Baldwin
- Jon E. GrantJGJon E. Grant
- Samuele CorteseSCSamuele Cortese
Open Access
- 20 November 2024
- journal article
- research article
- Published by Cambridge University Press (CUP) in Acta Neuropsychiatrica
- Vol. 37, 1-11
Abstract
Background: Placebo and nocebo effects are widely reported across psychiatric conditions, yet have seldom been examined in the context of gambling disorder. Through meta-analysis, we examined placebo effects, their moderating factors, and nocebo effects, from available randomised, controlled pharmacological clinical trials in gambling disorder. Methods: We searched, up to 19 February 2024, a broad range of databases, for double-blind randomised controlled trials (RCTs) of medications for gambling disorder. Outcomes were gambling symptom severity and quality of life (for efficacy), and drop outs due to medication side effects in the placebo arms. Results: We included 16 RCTs (n = 833) in the meta-analysis. The overall effect size for gambling severity reduction in the placebo arms was 1.18 (95%CI 0.91–1.46) and for quality of life improvement was 0.63 (0.42-0.83). Medication class, study sponsorship, trial duration, baseline severity of gambling and publication year significantly moderated effect sizes for at least some of these outcome measures. Author conflict of interest, placebo run-in, gender split, severity scale choice, age of participants or unbalanced randomisation did not moderate effect sizes. Nocebo effects leading to drop out from the trial were observed in 6% of participants in trials involving antipsychotics, while this was less for other medication types. Conclusion: Placebo effects in trials of pharmacological treatment of gambling disorder are large, and there are several moderators of this effect. Nocebo effects were measureable and may be influenced by medication class being studied. Practical implications of these new findings for the field are discussed, along with recommendations for future clinical trials.Keywords
This publication has 42 references indexed in Scilit:
- Online gambling among young men: a rising tide?Trends in Urology & Men's Health, 2023
- Diverse predictors of treatment response to active medication and placebo in gambling disorderJournal of Psychiatric Research, 2021
- Association of Single-blind Placebo Run-in Periods With the Placebo Response in Randomized Clinical Trials of AntidepressantsJAMA Psychiatry, 2021
- Magnitude of the Placebo Response Across Treatment Modalities Used for Treatment-Resistant Depression in AdultsJAMA Network Open, 2021
- Prescribing in borderline personality disorder – the clinical guidelinesProgress in Neurology and Psychiatry, 2020
- Cochrane Handbook for Systematic Reviews of Interventions2019
- Industry sponsorship and research outcomeCochrane Database of Systematic Reviews, 2017
- Combined Pharmacotherapies and Behavioral Interventions for Alcohol DependenceJAMA, 2006
- Reliability and Validity of the Pathological Gambling Adaptation of the Yale-Brown Obsessive-Compulsive Scale (PG-YBOCS)Journal of Gambling Studies, 2005
- Nonspecific Medication Side Effects and the Nocebo PhenomenonJAMA, 2002